Wednesday, February 5, 2025 2/5/2025

Contrast Enhanced Mammography (CEM) to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

Award Number: R01CA258898
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Abstract A primary concern regarding current breast cancer detection and diagnosis is the large number of benign biopsies being performed. Annually in the United States, radiologists recall over five million women for diagnostic workup and perform over one million breast biopsies, with fewer than one in four diagnosed as cancer. The new BI-RADS 4 subset assessment categories of 4A/B/C enables new tailored approaches for “risk” based decisions in different subsets of cases. In this classification scheme, lesions rated as 4A have an expected probability of malignancy more than 2% and up to 10% and those rated as 4B have a probability of malignancy more than 10% and up to 50%. A recent publication evaluating the positive predictive value (PPV3) for 125,447 diagnostic exams collected in the American College of Radiology (ACR) National Mammography Database (NMD) demonstrated that 88% of biopsies were performed on BI-RADS 4A and 4B lesions. Thus, opportunity exists to identify novel ways to better classify these low probability lesions more accurately in order to improve PPV3 and reduce biopsy of actually benign findings for hundreds of thousands of women annually. We believe that an operationally simple, cost effective, contrast enhanced mammogram (CEM), performed during the patient's diagnostic evaluation, would be the best approach to improve accuracy of radiologists' decisions for need to biopsy lesions classified with mammography, tomosynthesis (DBT) or US as 4A or 4B. CEM uses iodine contrast with dual low and high KeV mammogram images to create a contrast enhancement map of the breast that directly overlays the mammogram, thus providing anatomic and kinetic information, similar to MRI. We found in a preliminary clinical trial that radiologists had higher true-positive rates and lower false-positive rates for biopsy recommendation with CEM than when using DBT and US. To validate those initial findings, we propose to prospectively and sequentially perform CEM on 1855 consenting women with BI- RADS 4A or 4B lesions detected on mammography, DBT or US. Prospectively radiologists will provide BI- RADS ratings for every lesion using DBT alone, then with US and finally with CEM. With pathology known and based on the study design to minimize case by radiologist potential biases, we plan to estimate the NPV level of CEM-based recommendations (overall and within the cases with conventionally confirmed biopsy recommendation) and demonstrate that it is sufficiently high, while leading to substantial reduction in biopsy recommendations for actually benign lesions. Our primary expectation is that the number of recommendations to biopsy benign lesions will decrease significantly (~20%), while maintaining high NPV (>95%) among the initial recommendations. Using a subset of prospectively collected verified cases we will conduct a multi- reader (MRMC) study to assess heterogeneity of CEM effects across radiologists, obtain generalizable results, and elucidate supplemental specific CEM performance by lesion characteristics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $336,218 )
2025	2025	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Detection and Diagnosis Research	000	4	12/5/2024	NON-COMPETING CONTINUATION	$336,218
														Subtotal = $336,218

Issue Date FY: 2024 ( Subtotal = $452,223 )
2024	2024	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Detection and Diagnosis Research	001	3	4/16/2024	NON-COMPETING CONTINUATION	$23,801
2024	2024	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Detection and Diagnosis Research	000	3	11/27/2023	NON-COMPETING CONTINUATION	$428,422
														Subtotal = $452,223

Issue Date FY: 2023 ( Subtotal = $466,297 )
2023	2023	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Detection and Diagnosis Research	001	2	3/14/2023	NON-COMPETING CONTINUATION	$38,065
2023	2023	UNIVERSITY OF PITTSBURGH, THE	4200 5TH AVE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Detection and Diagnosis Research	000	2	11/23/2022	NON-COMPETING CONTINUATION	$428,232
														Subtotal = $466,297

Issue Date FY: 2022 ( Subtotal = $471,449 )
2022	2022	UNIVERSITY OF PITTSBURGH, THE	4200 5TH AVE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Detection and Diagnosis Research	000	1	12/14/2021	NEW	$471,449
														Subtotal = $471,449

Grand Total All Awards = $1,726,187

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Contrast Enhanced Mammography (CEM) to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

Award Number: R01CA258898

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer